Biology of the papillomavirus infections: V.Vaccine developments;Biologie des infections a papillomavirus: V. Perspectives vaccinales

Annales de Biologie Clinique

Volumn 57, Issue 5, 1999, Pages 517-524

  Seilles, E ^a   Riethmuller, D ^a   Mougin, C ^b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b NONE

Author keywords

Cervical cancer; Papillomavirus; Prophylaxis; Therapeutic; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; ONCOPROTEIN; VIRUS DNA; VIRUS VACCINE; PAPILLOMA VIRUS VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER INCIDENCE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENOTYPE; HUMAN; IMMUNIZATION; INFECTION CONTROL; NONHUMAN; PAPILLOMA VIRUS; PRECANCER; UTERINE CERVIX CANCER; VIRUS INFECTION; ANIMAL; CYTOTOXICITY; GENETICS; IMMUNOLOGY; REVIEW; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CYTOTOXICITY, IMMUNOLOGIC; DNA, VIRAL; FEMALE; HUMANS; ONCOGENE PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0033193366     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Greslin I, Mougin C, Seilles E. Biologie des infections à papillomavirus. III. Réponse immunitaire. Ann Biol Clin 1998 ; 56 : 267-76.
2. Majewski S, Jablonska S. Immunology of HPV infection and HPV-associated tumors. Int J Dermatol 1998 ; 37 : 81-95.
3. Bosch FX, Manos MM, Munoz N, et al. International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer : a worldwide perspective. J Natl Cancer Inst 1995 ; 87 : 796-802.
4. Bosch FX, Munoz N. HPV infection and cervical disease : an european perspective. European HPV Clinical Summit meeting : greater protection against cervical cancer 1998 ; Vienne (Austria).
5. Tindle RW, Frazer IH. Human pathogenic papillomavirus. Curr Topics Microbiol Immunol 1994 ; 186 : 217-52.
6. Sherman ME, Schiffman MH, Strickler H, Hilesheim A. Prospects for a prophylactic HPV vaccine : rationale and future implications for cervical cancer screening. Diagn Cytopathol 1998 ; 18 : 5-9.
7. Tindle RW. Immunomanipulative strategies for the control of human papillomavirus associated cervical disease. Immunol Research 1997 ; 16 : 387-400.
8. Kutteh WH. Mucosal immunity in the human female reproductive tract. In : Ogra PL et al., ed. Mucosal immunology. San Diego, Academy Press, 1999 : 1423-34.
9. Crowley-Nowick PA, Bell MC, Brockwell R, et al. Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immunol 1997 ; 17 : 370-9.
10. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparaison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997 ; 65 : 1387-94.
11. Klavinskis LS, Barnfiel C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999 ; 162 : 254-62.
12. Touzé A, El Mehdaoui S, Sizaret PY, Mougin C, Munoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variant affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 1998 ; 36 : 2046-51.
13. Le Cann P, Touze A, Enogat N, et al. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV16 L1 capsids produced by recombinant baculovirus. J Clin Microbiol 1995 ; 33 : 1380-2.
14. Christensen ND, Reed CA, Cladel MM, Han R, Kreider JW. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996 ; 70 : 960-5.
15. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 1996 ; 7 : 373-82.
16. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995 ; 92 : 11553-7.
17. Donnelly JJ, Martinze D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with polynucleotide vaccine. J Infect Dis 1996 ; 713 : 314-20.
18. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995 ; 69 : 3959-63.
19. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995 ; 13 : 1509-14.
20. Kirnbauer R, Chandrachud LM, O'Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996 ; 219 : 37-44.
21. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WFH. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993 ; 74 : 945-53.
22. Dupuy C, Buzoni-Gatel D, Touzé A, et al. Cell mediated immunity induced in mice by HPV16 L1 virus-like particles. Microbiol Pathogenesis 1997 ; 22 : 219-25.
23. Nardelli-Haefliger D, Roden RBS, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997 ; 65 : 3228-36.
24. Di Fabio S, Medaglini D, Rush CM, et al. Vaginal immunization of cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV16 antigens. Vaccine 1998 ; 16 : 485-92.
25. Medaglini D, Oggioni MR, Pozzi G. Vaginal immunization with recombinant gram-positive bacteria. Am J Reprod Immunol 1998 ; 39 : 199-208.
26. Dupuy C. Vaccination anti-papillomavirus : réponse systémique et vaginale contre la protéine majeure de capside. TH. Univ. : Tours, 1998.
27. Livingston JB, Lu H, Robinson H, Anderson DJ. Immunization of the female genital tract with a DNA-based vaccine. Infect Immun 1998 ; 322-9.
28. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infections human papillomaviruses. J Virol 1990 ; 64 : 3151.
29. Touzé A, Coursaget P. In vitro gene transfert using human papillomavirus-like particles. Nucleic Acid Research 1998 : 1317-23.
30. Hines JF, Ghim S, Jenson AB. Prospects for human papillomavirus vaccine development : emerging HPV vaccine. Curr Opin Obstet Gynecol 1998 ; 10 : 15-9.
31. Coursaget P, Touzé A, Dupuy C. Les vaccins anti-papillomavirus. Virologie 1998 ; 2, no spécial : 75-86.
32. Liu L, McPherson GG. Antigen acquisition by dendritic cells : intestinal dendritic cells acquire antigen administered orally and can prime naive T cell in vivo. J Exp Med 1993 ; 177 : 1299-307.
33. Duggan-Keen M, Keating PJ, Cromme FV, Walboomers JMM, Stern P. Alterations in major histocompatibility complex expression in cervical cancer : possible consequences for immunotherapy. Papillomavirus Rep 1994 ; 5 : 3-9.
34. Mougin C, Bernard B, Lab M. Biologie des infections à papillomavirus II. Leur rôle dans la carcinogenèse du col utérin. Ann Biol Clin 1998 ; 56 : 21-8.
35. De Grujil TD, Bontkess HJ, Walboomers JM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective non intervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997 ; 89 : 630-8.
36. Greenstone HL, Nieland JD, De Visser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998 ; 95 : 1800-5.
37. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998 ; 240 : 147-57.
38. Munoz N, Crawford L, Coursaget P. HPV vaccine and their potential use in the prevention and treatment of cervical neoplasia. Papillomavirus Rep 1995 ; 6 : 54-5.
39. Keating PF, Cromme FV, Duggan-Keen, et al. Frequency of down-regulation of individual HLA-A alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995 ; 72 : 405-11.
40. Ossevoort MA, Feltkamp MCW, Van Veen KJH, Mezizf CJM, Kast WM. Dendritic cells as carriers for cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995 ; 18 : 86-94.
41. + cytotoxic T-cells : implication for vaccine design. Proc Natl Acad Sci USA 1995 ; 13 : 5845-9.
42. Krul MR, Tijhaar EJ, Kleijne JA, et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 1996 ; 43 : 44-8.
43. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992 ; 148 : 2617-21.
44. Meneguzzi G, Cerni C, Kieni MP, Lathes R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991 ; 181 : 62-9.
45. + cells and persistence of viral DNA after regression. J Virol 1997 ; 71 : 5540-8.
46. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein F, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997 ; 71 : 8467-74.
47. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation antigens. Proc Natl Acad Sci USA 1995 ; 92 : 11671-5.
48. De Bruijn MLH, Schuurhuis DH, Vierboom MPM, et al. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 1998 ; 58 : 724-31.
49. Hariharan K, Braslawsky G, Barnett RS, Berquist LG, Hugnh T, Hanna N, Black A. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 1998 ; 12 : 1229-35.
50. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell reponses of patients with human papillomavirus type 16-positive cervical lesions against a human leucocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996 ; 56 : 582-8.
51. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996 ; 347 : 1523-7.